A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab

Fessas, P., Lee, H., Ikemizu, S., Janowitz, T. (April 2017) A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol, 44 (2). pp. 136-140. ISSN 0093-7754

URL: https://www.ncbi.nlm.nih.gov/pubmed/28923212
DOI: 10.1053/j.seminoncol.2017.06.002

Abstract

T-cell checkpoint inhibition has a profound impact on cancer care and the programmed cell death protein 1 (PD-1)-targeted antibodies nivolumab and pembrolizumab have been two of the lead molecules of this therapeutic revolution. Their clinical comparability is a highly relevant topic of discussion, but to a significant degree is a consequence of their molecular properties. Here we provide a molecular, preclinical, and early clinical comparison of the two antibodies, based on the available data and recent literature. We acknowledge the limitations of such comparisons, but suggest that based on the available data, differences in clinical trial outcomes between nivolumab and pembrolizumab are more likely drug-independent than drug-dependent.

Item Type: Paper
Subjects: organs, tissues, organelles, cell types and functions > cell types and functions > cell types > T cells
organs, tissues, organelles, cell types and functions > cell types and functions > cell types > T cells
organs, tissues, organelles, cell types and functions > cell types and functions > cell types > T cells

bioinformatics > genomics and proteomics > genetics & nucleic acid processing > protein structure, function, modification > protein types > antibodies
diseases & disorders > cancer > drugs and therapies > Immunotherapy
CSHL Authors:
Highlight: Janowitz, Tobias
Depositing User: Matthew Dunn
Date: April 2017
Date Deposited: 10 Oct 2018 16:55
Last Modified: 10 Oct 2018 16:55
PMCID: PMC5612055
Related URLs:
URI: http://repository.cshl.edu/id/eprint/37226

Actions (login required)

Administrator's edit/view item Administrator's edit/view item
CSHL HomeAbout CSHLResearchEducationNews & FeaturesCampus & Public EventsCareersGiving